◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY
Home › All stocks › IBRX › Net Income

ImmunityBio, Inc. (IBRX) Net Income 2021–2025

DATA UPDATED 2026-07-09

ImmunityBio, Inc. annual net income for fiscal 2025 was -$351 million, an increase of 15.0% from -$414 million in fiscal 2024. All figures are reported results from public filings — no estimates or projections.

IBRX Annual Net Income

Net Income (annual)2025-12-312024-12-312023-12-312022-12-312021-12-31
Net Income($351M)($414M)($583M)($417M)—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IBRX Quarterly Net Income

Net Income (quarterly)2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Net Income($633M)($62M)($67M)($93M)($130M)—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

More IBRX metrics: Revenue · Gross Profit · Operating Income · EPS · Free Cash Flow

All IBRX financial statements → Interactive IBRX charts →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.